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Abstract    24 
The importance of TANK binding kinase-1 (TBK1), a multimeric kinase that modulates 25 
inflammation and autophagy, in human health has been highlighted for the first time 26 
by the recent discoveries of mutations in TBK1 that underlie amyotrophic lateral 27 
sclerosis (ALS), frontotemporal dementia (FTD), normal tension glaucoma (NTG) or 28 
childhood herpes encephalitis (HSE). Gain-of-function mutations in TBK1 are 29 
associated with NTG, whereas loss-of-function mutations result in ALS/FTD or in HSE. 30 
In light of these new findings, we review the role of TBK1 in these seemingly unrelated, 31 
yet allelic diseases, and discuss the role of TBK1 in neurological diseases. This 32 
discovery has the potential to significantly increase our understanding of the 33 
molecular basis to these poorly understood neurological disorders. 34 
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TBK1 At Multiple Crossroads 44 
TBK1 (tumour necrosis factor (TNF) receptor associated factor NF-ĸB activator (TANK)-45 
binding kinase 1), also known as NAK or T2K, has recently attracted the attention of 46 
human geneticists, immunologists and neurologists alike for its critical role in central 47 
nervous system (CNS) pathology. It is an ubiquitously expressed serine-threonine 48 
kinase, belonging to the ‘non-canonical IĸB kinases (IKKs)’, recognized for its critical 49 
role in regulating type I interferon (IFN) production [1]. TBK1 is involved in the 50 
activation of various cellular pathways leading to IFN and pro-inflammatory cytokine 51 
production following infection [1], autophagic degradation of protein aggregates or 52 
pathogens [2–4], and homeostatic cellular functions such as cell growth and 53 
proliferation [5]. The genetics field has experienced an increased pace of discovery 54 
owing to the advances in sequencing technologies, which has begun to reveal a 55 
number of new genetic etiologies underlying various diseases. The recent discoveries 56 
of TBK1 heterozygous mutations in multiple human diseases has demonstrated the 57 
non-redundant role of this multifaceted protein in the CNS in particular [6–11] (Figure 58 
1). Here we review the pleiotropic role of TBK1 in light of new discoveries of human 59 
germline TBK1 mutations underlying neuroinflammatory diseases, including herpes 60 
simplex encephalitis (HSE), amyotrophic lateral sclerosis (ALS), frontal temporal lobe 61 
dementia (FTD) and normal tension glaucoma (NTG). The discovery comes either as 62 
part of a series of the first genetic etiologies defining a disease (HSE) or after a period 63 
of stagnant gene discovery (ALS, NTG). This finding suggests the involvement of new 64 
molecular pathways in disease pathogenesis which can lead to a better understanding 65 
of the causal mechanism underlying these neurological disorders. Furthermore, 66 
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knowledge gained from this can be used to develop new more effective therapies for 67 
these neurological disease with currently limited treatment options. 68 
 69 
TBK1 in Inflammatory Pathways 70 
TBK1 was first identified as a TANK interacting protein in mouse [12] with a role in 71 
controlling NF-ĸB-mediated responses as demonstrated by HEK293T cells co-72 
transfected with TBK1 and NF-kB promoter luciferase reporter [13]. However, in 73 
contrast to canonical IKKs (IKKα and IKKβ) that control NF-ĸB activation, the non-74 
canonical IKKs (TBK1 and IKKƐ) have since been found to play a more important role 75 
in the activation of transcription factors of the IFN-inducing interferon regulatory 76 
factor (IRF) family [14].  Indeed, TBK1 has been shown to play a key role in multiple 77 
cellular pathways, particularly inflammation and autophagy. Consequently, TBK1 sits 78 
at the crossroad of multiple inflammatory pathways, including NF-ĸB, and multiple 79 
IFN-inducing pathways.  80 
Pattern recognition receptors (PRRs) such as toll-like (TLRs), retinoic acid-inducible 81 
gene I (RIG-I)-like (RLRs), and cytosolic DNA receptors all play important roles in the 82 
recognition of invading pathogens leading to IFN production (Figure 2). The 83 
engagement of these innate immune sensors by their cognate ligands, such as LPS, 84 
double stranded RNA (dsRNA) or DNA, results in the production of cytokines which 85 
alert neighboring cells (including immune cells) of danger and foreign invasion, 86 
subsequently promoting the early events of defense against infection. Engagement of 87 
TLR3 by dsRNA recruits its adaptor TRIF (TIR-domain-containing adaptor-inducing 88 
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interferon-β), eventually activating TBK1, found complexed with NAK-associated 89 
protein 1 (NAP1) and IKKε (see Figure 1). Activated TBK1 phosphorylates IRF3 leading 90 
to its homodimerisation and translocation to the nucleus where they drive the 91 
expression of antiviral type-I and type-III IFNs (IFNα/β/λ) [1,15,16].  Apart from 92 
membrane-bound TLRs, cytosolic RLRs (RIG-I, melanoma differentiation-associated 5 93 
(MDA5) activated by viral RNA, [17–19] and cytosolic DNA receptors (cyclic guanosine 94 
monophosphate–adenosine monophosphate synthase (cGAS), stimulator of IFN 95 
genes (STING)) activated by dsDNA [20], all activate downstream TBK1 and induce IRF3 96 
and in some cases IRF7, [21–23] . Finally, another DEAD (Asp-Glu-Ala-Asp)-box 97 
helicase 3, X-linked protein (DDX3X) has also been shown to directly interact with TBK1 98 
in RAW264.7 murine macrophages following DNA and viral RNA recognition, thus 99 
leading to IFNβ production [24] (summarised in Figure 2). 100 
 101 
TBK1 in Autophagy 102 
Recent studies have described TBK1 as an important player in yet another critical 103 
cellular function, autophagy. Autophagy is an evolutionarily conserved homeostatic 104 
process of self-degradation that contributes to the maintenance of cell function at 105 
critical times by balancing sources through the turnover of long-lived proteins and 106 
organelles, and also, in the clearance of intracellular pathogens [25]. Autophagy is 107 
achieved by directing bulk cargo, such as protein aggregates, for degradation and/or 108 
recycling in lysosomes. It is a highly regulated process that is orchestrated by a variety 109 
of autophagy-related proteins (ATGs) such as beclin-1 (ATG6) that functions upstream 110 
of the pathway as an autophagy promoter (reviewed in [26,27]). Traditionally thought 111 
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to be a non-selective process, it has been increasingly found to recognize specific 112 
cargo. This specificity is mediated by recruitment of autophagy receptors such as 113 
optineurin, p62, nuclear dot protein 52 kDa (NDP52) and neighbour of BRCA1 gene 1 114 
(NBR1) [3,27–30] (Figure 2). These proteins bind simultaneously to ubiquitin residues 115 
on target cargo via their ubiquitin binding domain, and to phosphatidyletholamine-116 
conjugated microtubule-associated protein light chain 3 (LC3-II) proteins which are 117 
found on the inner leaflet of a forming autophagosomal membrane [27]. For post-118 
mitotic cells such as neuronal cells, autophagy is an essential survival mechanism by 119 
which toxic proteins are eliminated, as they are not able to dilute these proteins by 120 
mitosis [31,32]. A direct role of TBK1 in recycling protein aggregates has been shown 121 
via its role in phosphorylating the autophagy receptor optineurin [33]. TBK1 co-122 
localised with optineurin and cell aggregates in an in vitro model of protein 123 
aggregation in HeLa cells as well as in a SOD1 transgenic mouse model of ALS [33]. 124 
TBK1 has also been found to play a role in the autophagic elimination of invading 125 
intracellular pathogens such as Salmonella, Mycobacteria, and herpes simplex virus-1 126 
(HSV1) in human and murine cell lines [2–4].  127 
The role of TBK1 in selective autophagy has been extensively studied in Salmonella 128 
where it associates with optineurin and NDP52 in targeting ubiquitinated Salmonella 129 
for autophagic clearance (Figure 2) [2,34]. NDP52 is thought to act upstream of 130 
optineurin by directing TBK1 into the vicinity; TBK1 is then able to phosphorylate 131 
optineurin. TBK1 is also involved in autophagic clearance of Mycobacterium 132 
tuberculosis in RAW264.7 murine macrophages where it has been shown to 133 
phosphorylate the autophagy receptor p62, enhancing its binding to 134 
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polyubiquitinated bacteria [4]. Moreover, TBK1 is particularly crucial for the 135 
maturation of the autophagosome into the hydrolytic autophagolysosome leading to 136 
degradation of p62 and its affiliated cargo [4]. Autophagy is also critical in HSV1 137 
infections, demonstrated by the virus’ ability to inhibit host autophagy through two 138 
virally-encoded products US11 and ICP34.5 [35–37]. And, although TBK1 has not been 139 
directly implicated in HSV1-mediated autophagy, the virally-encoded autophagy 140 
antagonist ICP34.5 has been shown to bind and inhibit TBK1 in a mouse model of HSV1 141 
infection [38]; this interaction has been been suggested to play a role in limiting the 142 
propagation and dissemination of HSV1 to the CNS (35]. Hence, TBK1 has been 143 
implicated in pathogen clearance via autophagy contributing to cell-autonomous 144 
immunity. The two TBK1-regulated processes, autophagy and IFN signaling are not 145 
mutually exclusive as their crosstalk has been reported. Upon HSV1 infection, cGAS 146 
was shown to bind Beclin-1 leading to the suppression of IFN production, and a 147 
simultaneous increase in the autophagosomal clearance of cytosolic viral DNA in mice 148 
bone marrow-derived macrophages (BMDMs) [39]. Similarly, mouse BMDMs were 149 
shown to induce type-I IFN following mycobacterial infection as well as trigger 150 
autophagic clearance of the pathogen in a TBK1 dependent manner via cGAS [40]. 151 
Although mouse models of TBK1 deficiency have contributed to our fundamental 152 
understanding of TBK1 function, particularly in immune signaling (see Box 1), they 153 
have not been predictive of the human phenotypes associated with human TBK1 154 
mutations as neurological phenotypes were not assessed. 155 
 156 
TBK1 Variants in Human Diseases 157 
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Mutations in Human TBK1 Predispose to HSE: Impairment in IFN Production 158 
Herpes simplex encephalitis (HSE) is a devastating neurological disease caused by 159 
HSV1 infection of the CNS. HSV1 is a neurotropic dsDNA alphaherpesvirus usually 160 
causing asymptomatic or benign disease in the general population. With an incidence 161 
of 1-2 individuals per million annually, HSE is a sporadic and rare manifestation of 162 
HSV1 infection [41]. Peak incidence of HSE follows a bimodal curve, affecting children 163 
between three months-six years of age, coincident with the time of primary HSV-1 164 
infection, and adults over 50 years of age, probably due to reactivation of latent HSV1 165 
infection [42]. It is thought to reach the CNS through the nasal or oral epithelium via 166 
the olfactory or trigeminal nerves [43]. It exerts a wide spectrum of clinical features 167 
ranging from necrosis of brain tissue, fever, altered behavior and disturbed 168 
consciousness usually in the absence of viremia. Standard current treatment of 169 
acyclovir has greatly improved survival rates of HSE patients, although survivors tend 170 
to suffer from lifelong neurological sequelae characterized by global developmental 171 
delay, intellectual deficiencies, seizures and motor skill disturbances [42,44,45]. HSE 172 
has never been associated with any particularly neurovirulent strain of HSV1, and 173 
hence it had been a rare idiopathic complication of HSV1 infection until the 174 
identification of single gene defects in the TLR3-IFN pathway, including autosomal 175 
dominant TBK1 deficiency [46]. 176 
Isolated childhood HSE can be caused by at least seven different genetic etiologies of 177 
the TLR3-IFN pathway.  These include autosomal recessive (AR) UNC93B1, autosomal 178 
dominant (AD) and AR TLR3, AD and AR TRIF, AD TRAF3, AD TBK1, and AD IRF3 179 
deficiencies, reflecting the importance of IFN production in defense against HSV1 180 
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infection (Figure 2) [6,47–52]. For both AD and AR defects however, the clinical 181 
penetrance of HSE is incomplete, as healthy family members have also found to carry 182 
HSE-causing mutations [6,47–50,52]. This is consistent with HSE being almost 183 
invariably sporadic, with only four multiplex families reported since 1941 [6,48,50]. 184 
There is however, complete penetrance of the mutations at the cellular level. For 185 
instance, functional studies of fibroblasts or induced pluripotent stem cell (iPSC)-186 
derived neuronal cells derived from these patients have revealed a common defect in 187 
antiviral type-I and type-III IFN production. However, IFN responses have shown to be 188 
intact in these patient cells, underscoring the importance of IFN production in clearing 189 
HSV1 infection [53,54].  190 
TLR3 signaling has also been studied in cells from patients with HSE. Endosomal TLR3 191 
recognizes dsRNAs [55], produced during the HSV1 life cycle [56,57], triggering the 192 
production of anti-viral type-I and type-III IFNs (IFNα/β, IFNλ) (Figure 2). These IFNs 193 
are essential in controlling viral infection and establishing an anti-viral state by 194 
activating various host mechanisms that inhibit viral propagation and spread, such as 195 
translational arrest, and the induction of apoptosis [35,58]. Surprisingly, despite 196 
having impaired TLR3-mediated IFN production by their fibroblasts, these patients are 197 
otherwise healthy and are not susceptible to other viral infections, presumably 198 
because of the presence of intact and protective TLR3-independent IFN signalling 199 
mediated by cytosolic receptors such as RLRs [17].  200 
 201 
Two different heterozygous missense TBK1 mutations were also found in two 202 
unrelated European children with HSE (p.G159A and p.D50A respectively) (Figure 1, 203 
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Table 1). Both heterozygous mutations occur in the kinase domain of the protein; 204 
however, one produces its effect in a dominant negative fashion (p.G159A) whilst the 205 
other is dominant by haploinsufficiency (p.D50A) [6]. The patient carrying the G159A 206 
mutation developed HSE at 7 years of age and subsequently developed epilepsy and 207 
cognitive disabilities [6]. The patient carrying the D50A mutation developed HSE at 11 208 
months of age and suffered from obesity as well as cognitive and motor dysfunctions 209 
thereafter [6]. Despite normal protein and mRNA expression, the G159A mutant allele 210 
produced a kinase-dead TBK1. And, in terms of IFN signaling, the G159A mutation led 211 
to impairment of IRF3 phosphorylation, resulting in lack of IFN and IFN production 212 
but normal IL-6 production upon TLR3 stimulation of patient dermal fibroblasts in vitro 213 
[6].  Because overexpression of this mutant allele in control human fibroblasts (with 214 
endogenous wild type TBK1) led to blocked IFN production, this suggested that the 215 
impaired signaling occurred due to the dominant negative effect of the mutant allele 216 
over the wild type allele. The D50A mutant allele however, exhibited poor expression 217 
at both protein and mRNA levels and hence, loss of kinase activity. Despite this, it 218 
showed normal poly I:C responsiveness in fibroblasts as demonstrated by normal IRF3 219 
activation and IFN, IFN, and IL-6 production [6]. It was therefore concluded that the 220 
D50A allele is dominant due to haploinsufficiency. Autophagy function was not tested 221 
in these patients. Of note, both patients’ fibroblasts presented intact RLR-mediated 222 
IFN production, suggesting that TBK1 function was unaffected downstream of the 223 
cytosolic PRRs [6]. However, fibroblasts from both patients were unable to control 224 
HSV1 or VSV infections, suggesting that a functional TBK1-dependent TLR3-IFN 225 
pathway was necessary for limiting viral replication [6]. It should be noted that one 226 
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cannot rule out other, as yet to be defined mechanisms that might also potentially 227 
contribute to HSE pathology  (Box 2). 228 
 229 
TBK1 Variants Can Predispose Individuals to ALS, ALS-FTD, or FTD: Implications for 230 
Aberrant Autophagy 231 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Charcot’s 232 
disease, is a typically adult-onset neurodegenerative disease characterized by 233 
progressive muscle wasting which is usually fatal [59]. First described in 1869 by Jean-234 
Martin Charcot [60], it has a an incidence of 1-2 per 100, 000 adults per year typically 235 
affecting individuals of 50-60 years old [59].  Approximately 90% of ALS cases are 236 
sporadic and the remaining 10% are familial [59]. Parental consanguinity does not 237 
seem to be higher than in the general population. ALS is associated with progressive 238 
loss of upper and lower motor neurons that lead to weakening and atrophy of 239 
muscles, paralysis and eventually death mostly due to respiratory failure typically 240 
within 2 to 3 years after diagnosis [61]. Neuropathological features include extensive 241 
degeneration of motor neurons in anterior roots of the spinal cord and brainstem, 242 
corticospinal tract and loss of large pyramidal neurons residing in the primary motor 243 
cortex. Another hallmark feature is the presence of protein aggregates in 244 
degenerating neurons, most of which are ribonuclear proteins, such as transactive 245 
response (TAR) DNA-binding protein 43 (TDP-43). Proposed pathophysiological 246 
mechanisms of ALS include oxidative stress [62], impaired mitochondrial functions 247 
[63], perturbed axonal transport that lead to accumulation of organelles [64] and 248 
neuroinflammation that is triggered by motor neuron degeneration [65]. 249 
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Furthermore, 15% of ALS patients develop cognitive abnormalities reminiscent of 250 
frontotemporal lobar dementia (FTD), and 15% of FTD patients have features of ALS 251 
[66]. Recent studies that have looked at CNS tissues of FTD and ALS patients have 252 
proposed that ALS and FTD form part of the same disease spectrum with common 253 
underlying features such as the presence of the TDP-43 proteins that accumulate in 254 
the cytoplasm of neurons [67].  Currently, there are no effective therapies available 255 
for this debilitating and lethal disease.  256 
Many genes associated with ALS pathogenesis have been identified, including 257 
superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TDP-43), FUS RNA-258 
binding protein (FUS), Alsin (ALS2), Ubiquilin-2 (UBQLN2), Optineurin (OPTN), 259 
Sequestosome 1 (SQSTM1), Valosin-containing protein (VCP), and chromosome 9 260 
open reading frame 72 (C9orf72) amongst many others, although these collectively 261 
account for less than one third of all ALS cases [68–71] (reviewed in[72]). These genes 262 
were all identified initially in familial forms of ALS through linkage studies, and then, 263 
further found in sporadic cases. In ALS patients, these mutations are all typically 264 
mono-allelic, with the exception of some forms of disease including SOD1, OPTN, FUS 265 
and ALS2 mutations amongst others [70,73–76]. Protein aggregates are a hallmark of 266 
the disease, comprised by proteins which are encoded by genes linked to causing ALS, 267 
e.g. SOD1, TARDBP, FUS. These protein aggregates can be stained with antibodies 268 
against two autophagy receptors previously mentioned, p62 and optineurin, which 269 
have also been implicated in the pathogenesis of ALS (Figure 2) [73,77]. Further 270 
evidence implicating autophagy as a putative pathogenic mechanism for ALS, came 271 
from a report by Cirulli et al. identifying for the first time, TBK1 as a new ALS-272 
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susceptibility gene in a whole exome sequencing (WES) study of 2,869 ALS patients 273 
and 6, 405 controls, along with two other autophagy genes OPTN and SQSTM1 274 
(encoding optineurin and p62 respectively) [7]. Although none of the TBK1 variants 275 
found were functionally assessed in this study, heterozygous TBK1 mutations were 276 
found to be significantly enriched in patients when compared to controls (1.099% of 277 
cases and 0.194% of controls). In particular, TBK1 mutations were bioinformatically 278 
predicted to constitute ‘loss-of-function’ (LoF) mutations, including nonsense, splice 279 
site, frameshift,  and deletions in TBK1, (the latter were 10-fold more prevalent in 280 
patient cases) [7] (Table 2). 281 
This finding was further supported by Freischmidt et al., who identified genome-wide 282 
enrichment of TBK1 mutations in 252 familial ALS patients [8]. WES of 13 European 283 
Caucasian families diagnosed with ALS or ALS-frontotemporal dementia (FTD) 284 
identified 8 heterozygous LoF classes of variants in TBK1. These mutations were 285 
assessed for optineurin binding as well as their ability to induce IFNβ signaling (IRF3 286 
activation and IFN induction) in HEK293T cells (Figure 1, Table 1). These LoF mutations 287 
were shown to have no mRNA or protein expression, consistent with 288 
haploinsufficiency (Figure 1, Table 1). Specifically, patients’ cells (lymphoblastoid cell 289 
lines, keratinocytes, or fibroblasts), heterozygous for four of these variants, (Y185X, 290 
I450KfsX15, T77WfsX4, A417X), exhibited 50% reduced expression of TBK1 at the 291 
mRNA and/or protein levels [8]. Furthermore, HEK293T cells expressing two of the 292 
other mutations (T320QfsX40, V479EfsX4) showed no allele-specific expression of the 293 
TBK1 protein. A number of these LoF variants was tested for optineurin binding and 294 
IFN induction in 293 cells, which showed complete impairment of both TBK1-related 295 
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functions (Table 1). These variants were therefore reported to exert their effect via 296 
haploinsufficiency and determined to be causative.  The p.690-713del variant, despite 297 
producing a TBK1 protein product, had a 24 amino acid deletion in the C-terminal 298 
CCD2 domain, specifically at the optineurin binding site, resulting in impaired binding 299 
to optineurin. The causative LoF mutations (Figure 1), p.Y185X, p.I450KfsX15, 300 
p.T77WfsX4, p.A417X, p.T320QfsX40, p.V479EfsX4, p.690-713del (R440X was not 301 
assessed), resulted in either haploinsufficiency or loss of CCD2 function and were 302 
found in ALS-FTD patients (approximately 50% of cases presented significant cognitive 303 
disabilities, often progressing towards FTD), as seen with other familial forms of the 304 
C9orf72 mutation, extending the TBK1 phenotype to include FTD [8]. The clinical 305 
penetrance of these mutations was high, with 33 out of 40 carriers harboring TBK1 306 
mutations over the age of 60 years old, presenting ALS [8]. 307 
In addition, Freischmidt et al. reported 9 missense mutations and 1 in-frame deletion 308 
in ALS, ALS-FTD patients. Although missense mutations were not found to be enriched 309 
in their genetic analysis, in vitro assays (optineurin binding and IFN induction in 293 310 
cells) on a selection of these mutations showed impaired TBK1 function, however the 311 
authors suggest further experiments to determine pathogenicity of these missense 312 
mutations (Figure 1, Tables 1 and 2) [8]. One particular missense variant located in the 313 
CCD2 domain, E696K, resulted in a failure of TBK1 to bind optineurin following co-314 
immunoprecipitation in HEK293T cells. This mutation as well as the E643del mutation, 315 
also seen in Freischmidt et al, were identified as causative in a separate study of 316 
isolated FTD cases, and showed reduced expression in patient post-mortem cerebellar 317 
tissue and lymphoblast cells respectively [9,11]. Additional mutations in French ALS, 318 
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ALS-FTD, and isolated FTD patient cohorts, as well as a Chinese ALS patient have been 319 
subsequently reported (Table 2) [78,79]. Disease-causing mutations as reported in the 320 
literature are shown in Figure 1, whereas Tables 1 and 2 list variants of unknown 321 
pathogenicity that have been molecularly characterized, or not, respectively. In 322 
summary, these studies have now provided a link between TBK1 and other previously 323 
identified ALS genes SQSTM1 and OPTN, to autophagy, suggesting that this is an 324 
important cellular regulatory mechanism, which, when dysfunctional, can contribute 325 
to neurodegeneration, as observed in ALS disease. Full functional characterization of 326 
these TBK1 mutations in context of autophagy function, using autophagy flux assays 327 
for example, will be necessary to unequivocally prove autophagy dysregulation. It will 328 
be interesting to see if IFN signaling is also impaired in these diseases as autophagy 329 
has been shown to regulate IFN responses [39,40] (Box 2). 330 
 331 
TBK1 Duplications and Predisposition to Glaucoma: Gain-of-function Mutations 332 
Glaucoma is the leading cause of adult-onset blindness with a prevalence of 1.86% in 333 
the US in adults over 40 years old; it is a neurodegenerative disease affecting the 334 
retinal ganglion cells of the optic nerve, usually resulting in irreversible ocular damage 335 
[80,81]. Glaucoma can be classified into two subtypes; primary open angle glaucoma 336 
(POAG), characterized by high intraocular pressure causing damage to the optical 337 
nerves, and normal tension glaucoma (NTG), associated with normal intraocular 338 
pressure (IOP) [82,83]. Single-gene heterozygous mutations underlying both types of 339 
glaucoma have been described, and are thought to account for 5% of all cases [84]. 340 
Heterozygous nonsense mutations in the myocilin gene (MYOC), a protein found in 341 
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the trabecular meshwork and the ciliary body of the eye thought to regulate IOP, are 342 
known to cause POAG with relatively high penetrance (98.6%) and recent reports 343 
describe familial and sporadic NTG patients to harbour heterozygous mutations in 344 
OPTN [84]. Mutant OPTN (p.E50K) has been shown to form aggregates of insoluble 345 
protein in neuronal cells derived from NTG patient’s iPS cells, thus leading to cell death 346 
[83]. TBK1 has also been found to interact with mutant E50K OPTN protein, 347 
contributing to insolubility of the latter, and consequently, to NTG pathology [83]. 348 
Moreover, familial analysis of NTG patients has revealed several highly penetrant copy 349 
number variants encompassing a chromosome 12 region, and inclusive of TBK1 (Figure 350 
1, Tables 1 and 2) [10]. This heterozygous duplication has been associated with higher 351 
TBK1 transcription levels in skin fibroblasts derived from the patients, suggesting a 352 
TBK1 gain of function underlying glaucoma [10]. Hence NTG TBK1 mutations present 353 
a different genetic etiology than that which has been observed in TBK1 deficiency 354 
models underlying HSE, ALS, ALS-FTD, or FTD. Furthermore, this gene duplication has 355 
since been observed in other cohorts of NTG patients (Table 2) [85,86]. The original 356 
study also reported three missense heterozygous TBK1 variants in the patient cohort 357 
(p.S151F, p.L306I, p.V464A) although they remain of unknown pathogenicity  (Table 358 
2) [10].   359 
 360 
TBK1: One Gene, Multiple Diseases. Molecular Basis to Disease Pathogenesis  361 
It comes as no surprise that TBK1 would be important for human health, as it is highly 362 
conserved evolutionary as well as in the general population (only 1 commonly 363 
occurring missense variant has been reported in 66,000 WES individuals Exome 364 
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Aggregation Consortium (ExAC) [87]). HSE, ALS, FTD, and NTG are diverse diseases 365 
caused either by infection, or protein aggregate accumulation in neuronal cells. Of 366 
course, the identified genes associated with these diseases explain only a proportion 367 
of all patient cases, suggesting that further genetic heterogeneity is present. Indeed, 368 
these diseases share heterozygous mutations in TBK1, an essential multifunctional 369 
kinase participating in two distinct pathways: innate immune inflammatory signaling 370 
(TLR3-IFN pathway) and autophagy. So what potential mechanisms render this gene 371 
responsible for such clinically-distinct pathological conditions?  372 
 373 
TBK1 Domain-specific Mutations 374 
Mutations in a single gene can give rise to different phenotypes due to domain specific 375 
mutations which determine modular impairment of a multimeric protein. Examples of 376 
this are not uncommon and include the STAT1 deficiencies [88]. Interestingly, none of 377 
the HSE and NTG mutations have been found in ALS, isolated FTD or ALS-FTD patients, 378 
although identical mutations have been observed in the latter three diseases. The HSE 379 
mutations were shown to occur exclusively in the kinase domain, resulting in allele-380 
specific impairment of IFNβ induction [8]. This may possibly suggest that the kinase 381 
domain is particularly important for effective IFN production. (Figure 1, Table 1).  In 382 
contrast, Freischmidt et al. reported CCD2 domain mutations in TBK1, impairing 383 
optineurin binding but maintaining normal IFNβ promoter activation suggesting that 384 
TBK1 autophagy function may play a protective role in ALS and FTD [8]. As such, TBK1 385 
mutations affecting domain specificity might represent an underlying factor 386 
contributing to differential phenotypes in these diseases. 387 
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 388 
Subcellular Localization and Tissue Specificity of TBK1 389 
On a similar note, mutations affecting specific protein interactions could affect 390 
subcellular localization of TBK1, which might potentially affect disease manifestation. 391 
In that regard the subcellular localization of TBK1 has been shown to determine its 392 
role in different pathways [89]. For example, one study reported that TBK1 could 393 
interact with each of its adaptors TANK, SINTBAD, and NAP1 in a mutually exclusive 394 
manner, such that TBK1 activation following viral infection was TBK1-TANK-395 
dependent and specifically occurring in perinuclear compartment, whereas TBK1-396 
NAP1 co-localized with autophagosomes in HeLa cells [89]. Hence, it is conceivable 397 
that mutations which alter the spatial distribution of TBK1 in a cell might be connected 398 
to altered cellular phenotypes that are manifested in different disease pathologies. 399 
Moreover, despite its ubiquitous expression, TBK1 may have cell type-specific roles 400 
favoring specific signaling pathways. This has been difficult to determine, as most 401 
functional assays have been carried out on leukocytes or fibroblasts, as opposed to 402 
the relevant CNS cells affected in these disease-types. In light of the fact that CNS cells 403 
selectively utilise autophagy over IFN signaling during viral infections, such putative 404 
tissue specificity might play a larger role than previously thought [90]. Consequently, 405 
intrinsic spatial localization characteristics combined with domain and tissue 406 
specificity might play a role in how various TBK1 mutations within the same gene are 407 
manifested in different diseases. 408 
 409 
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TBK1 Mutation Type 410 
It is possible to consider that the type of TBK1 mutation (loss-of-function (LoF), gain-411 
of-function (GoF), dominant negativity, haploinsufficiency) might also play a role in 412 
determining disease type. NTG is a GoF model of TBK1 pathogenicity, due to TBK1 413 
duplications. In contrast, ALS and FTD have been largely associated with LoF 414 
heterozygous mutations resulting in haploinsufficiency. By inference, a moderate 415 
reduction of TBK1 expression (~50%) by haploinsufficiency, due to residual expression 416 
from the wild type allele, could presumably affect TBK1-dependent autophagy 417 
function. On the other hand, a missense HSE-causing TBK1 mutation has been shown 418 
to result in a dominant negative effect on the wild type allele, leading to impaired IFN 419 
signaling, and suggesting that very low overall levels of functional TBK1 could impact 420 
the IFN signaling pathway [6]. The difference in absolute levels of TBK1 due to its 421 
respective mutations might be responsible, or capable of modulating the outcome for 422 
such observed differences in cellular phenotypes. This may suggest that different 423 
mutations may have different thresholds of effective TBK1 function, which could 424 
result in disparate diseases. 425 
 426 
Further Implications for HSE/ALS Pathogenesis  427 
HSE, ALS-FTD and NTG have not previously been proposed as having a similar disease 428 
spectrum, however we propose that their common genetic etiology raises questions 429 
about a possible shared pathogenesis and implications for new treatment avenues 430 
(Figure 3). This may be due to TBK1’s niche role, possibly determined by tissue 431 
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specificity, in CNS inflammation. Despite sharing ‘TBK1’ features with HSE, ALS and 432 
FTD, NTG presents a GoF TBK1 model of which sets it apart from the LoF TBK1 model 433 
of other diseases. In light of the evidence discussed here suggesting a shared disease-434 
causing gene, why do we not see co-occurrence of these diseases? There are no 435 
reports on the co-occurrence of HSE and ALS in the same individual. This may be 436 
because both HSE and ALS are exceedingly rare events (HSE 1-2/1million/yr; ALS 437 
2/100,000/yr) such that the co-occurrence of disease would be highly unlikely, 438 
especially when incomplete penetrance is a feature of both diseases. TBK1’s 439 
involvement in ALS is progressive (accumulation of protein aggregates) resulting in the 440 
manifestation of disease pathology whereas in HSE, exposure and infection by HSV1 441 
is necessary in order to reveal a phenotype. Furthermore, the HSV1 seropositivity rate 442 
among adults ranges from 40-87%, contributing to this reduced penetrance [91]. 443 
However, as the age of onset for ALS-FTD is much higher than that of HSE, which peaks 444 
in early childhood, it would be of interest to carefully follow long-term outcomes of 445 
HSE patients, as ALS symptoms may have yet to manifest. Prior to the advent of 446 
acyclovir in the 1980s, HSE patients would not have survived and therefore we do not 447 
have any long-term follow-up. Additionally, the fitness of patients post-HSE is 448 
reduced, with mortality rates up to 30% and over 50% suffering from severe sequelae, 449 
such that they may never reach age of onset for ALS [42,44]. Testing for the presence 450 
of protein aggregates in CNS samples from HSE patients would reveal whether a 451 
similar pathology is observed. Of note, both reported HSE patients with TBK1 452 
deficiency were also found to have developed cognitive impairment and/or motor 453 
disabilities subsequent to HSE [6]. HSE patients with other TLR3-IFN deficiencies (not 454 
TBK1) would probably have low risk of developing ALS if the molecular defect of HSE 455 
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is truly restricted to IFN signaling and is autophagy independent.  Testing HSV1 456 
serology in all ALS-FTD patients, in particular those with TBK1 mutations may be 457 
informative. The reciprocal experiments of testing autophagy and IFN signaling in HSE 458 
vs. ALS/FTD patient cells might help address how similar HSE and ALS/FTD disease 459 
states are, as currently, these TBK1 functions in patient cells have not been fully 460 
explored in any of the studies discussed here. 461 
 462 
Concluding Remarks 463 
Advances in sequencing technologies have begun to reveal a growing number of single 464 
gene variants that can underlie a diverse range of diseases [92–94]. These types of 465 
studies will undoubtedly reveal further novel genetic models to explain disease 466 
pathogenesis. In fact, mutations associated with a particular disease, which are found 467 
in other atypically presenting diseases, would have been overlooked if it were not for 468 
large-scale sequencing studies. The concept that mutations in a single gene can cause 469 
a broad spectrum of disorders has been well documented [95,96]. This effect might 470 
be mediated through different mechanisms, including i) mutations occurring in 471 
domain-specific regions of a given multimeric protein, ii) qualitative differences 472 
resulting from a certain type of mutation, or iii) subcellular localization/tissue 473 
specificity. Human partial TBK1 deficiency results in 474 
neuroinflammatory/neurodegenerative disorders of the CNS such as HSE, ALS, ALS-475 
FTD, whereas TBK1 GoF results in NTG. These conditions are probably a consequence 476 
of dysregulated autophagy (ALS, FTD, NTG) or of impaired IFN signaling (HSE). The 477 
surprisingly important role of this protein in the CNS, particularly its role in autophagy, 478 
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is consistent with other reports that post mitotic cells such as neurons depend on 479 
autophagy to deal with inflammation and cell survival following infection [90]. Not 480 
only does this suggests a common underlying disease etiology but also raises more 481 
questions about the pathogenesis of these diseases (see Outstanding Questions). 482 
Despite the exciting and unexpected finding of TBK1 involvement in these diseases, 483 
further studies to confirm the pathogenic mechanism underlying TBK1 defects in 484 
context of neuroprotection and neuroinflammation are needed to fully appreciate its 485 
role in disease (See Outstanding Questions). Any further knowledge gained form this 486 
can be applied to ameliorate treatment options for these debilitating diseases, 487 
particularly focusing on the neuroprotective aspects of intervention as current 488 
treatment for HSE, ALS, FTD and NTG are limited (Box 3). Any lessons learnt in one of 489 
the TBK1-disease could be extended to the other, which can lead to beneficial 490 
advances in all TBK1-neuroinflammatory diseases.  491 
 492 
Acknowledgements 493 
We thank Elizabeth T. Cirulli and Tim Harris for providing a detailed list of all TBK1 494 
mutations. We thank Inge A. Meijer, Aubrey J. Cunnington, Serge Mostowy, and Beth 495 
Holder for helpful discussions. LA is supported by the Chancellor’s Scholarship of 496 
Universiti Brunei Darussalam; VSS, by the Medical Research Foundation and JLC is a 497 
member of the Howard Hughes Medical Institute. Our studies are partly funded by 498 
NIH grant number 2R01NS072381-05 (JLC and SYZ), ANR award IEIHSEEI (SYZ) and the 499 
Medical Research Foundation (VSS). 500 
 23 
  501 
 24 
References 502 
1  Fitzgerald, K.A. et al. (2003) IKKepsilon and TBK1 are essential components of 503 
the IRF3 signaling pathway. Nat. Immunol. 4, 491–6 504 
2  Thurston, T.L.M. et al. (2009) The TBK1 adaptor and autophagy receptor 505 
NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat. Immunol. 506 
10, 1215–21 507 
3  Wild, P. et al. (2011) Phosphorylation of the autophagy receptor optineurin 508 
restricts Salmonella growth. Science 333, 228–33 509 
4  Pilli, M. et al. (2012) TBK-1 promotes autophagy-mediated antimicrobial 510 
defense by controlling autophagosome maturation. Immunity 37, 223–34 511 
5  Clément, J.-F. et al. (2008) The IKK-related kinases: from innate immunity to 512 
oncogenesis. Cell Res. 18, 889–99 513 
6  Herman, M. et al. (2012) Heterozygous TBK1 mutations impair TLR3 immunity 514 
and underlie herpes simplex encephalitis of childhood. J. Exp. Med. 209, 515 
1567–82 516 
7  Cirulli, E.T. et al. (2015) Exome sequencing in amyotrophic lateral sclerosis 517 
identifies risk genes and pathways. Science 347, 1436–41 518 
8  Freischmidt, A. et al. (2015) Haploinsufficiency of TBK1 causes familial ALS and 519 
fronto-temporal dementia. Nat. Neurosci. 18, 631–6 520 
9  Pottier, C. et al. (2015) Whole-genome sequencing reveals important role for 521 
TBK1 and OPTN mutations in frontotemporal lobar degeneration without 522 
 25 
motor neuron disease. Acta Neuropathol. 130, 77–92 523 
10  Fingert, J.H. et al. (2011) Copy number variations on chromosome 12q14 in 524 
patients with normal tension glaucoma. Hum. Mol. Genet. 20, 2482–94 525 
11  Gijselinck, I. et al. (2015) Loss of TBK1 is a frequent cause of frontotemporal 526 
dementia in a Belgian cohort. Neurology 85, 2116–25 527 
12  Pomerantz, J.L. and Baltimore, D. (1999) NF-kappaB activation by a signaling 528 
complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO 529 
J. 18, 6694–704 530 
13  Tojima, Y. et al. (2000) NAK is an IkappaB kinase-activating kinase. Nature 404, 531 
778–782 532 
14  Chau, T.-L. et al. (2008) Are the IKKs and IKK-related kinases TBK1 and IKK-533 
epsilon similarly activated? Trends Biochem. Sci. 33, 171–80 534 
15  Sharma, S. et al. (2003) Triggering the interferon antiviral response through an 535 
IKK-related pathway. Science 300, 1148–51 536 
16  Yamamoto, M. et al. (2003) Role of adaptor TRIF in the MyD88-independent 537 
toll-like receptor signaling pathway. Science 301, 640–3 538 
17  Loo, Y.-M. and Gale, M. (2011) Immune signaling by RIG-I-like receptors. 539 
Immunity 34, 680–92 540 
18  Ishii, K.J. et al. (2006) A Toll-like receptor-independent antiviral response 541 
induced by double-stranded B-form DNA. Nat. Immunol. 7, 40–8 542 
 26 
19  Paz, S. et al. (2006) Induction of IRF-3 and IRF-7 phosphorylation following 543 
activation of the RIG-I pathway. Cell. Mol. Biol. (Noisy-le-grand). 52, 17–28 544 
20  Sun, L. et al. (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that 545 
activates the type I interferon pathway. Science 339, 786–91 546 
21  Saitoh, T. et al. (2009) Atg9a controls dsDNA-driven dynamic translocation of 547 
STING and the innate immune response. Proc. Natl. Acad. Sci. U. S. A. 106, 548 
20842–6 549 
22  Ishikawa, H. and Barber, G.N. (2008) STING is an endoplasmic reticulum 550 
adaptor that facilitates innate immune signalling. Nature 455, 674–8 551 
23  Kumar, H. et al. (2009) Pathogen recognition in the innate immune response. 552 
Biochem. J. 420, 1–16 553 
24  Soulat, D. et al. (2008) The DEAD-box helicase DDX3X is a critical component 554 
of the TANK-binding kinase 1-dependent innate immune response. EMBO J. 555 
27, 2135–46 556 
25  Klionsky, D.J. (2007) Autophagy: from phenomenology to molecular 557 
understanding in less than a decade. Nat. Rev. Mol. Cell Biol. 8, 931–7 558 
26  Klionsky, D.J. and Schulman, B.A. (2014) Dynamic regulation of 559 
macroautophagy by distinctive ubiquitin-like proteins. Nat. Struct. Mol. Biol. 560 
21, 336–45 561 
27  Stolz, A. et al. (2014) Cargo recognition and trafficking in selective autophagy. 562 
Nat. Cell Biol. 16, 495–501 563 
 27 
28  Kirkin, V. et al. (2009) A role for NBR1 in autophagosomal degradation of 564 
ubiquitinated substrates. Mol. Cell 33, 505–16 565 
29  Matsumoto, G. et al. (2011) Serine 403 phosphorylation of p62/SQSTM1 566 
regulates selective autophagic clearance of ubiquitinated proteins. Mol. Cell 567 
44, 279–89 568 
30  Mostowy, S. et al. (2011) p62 and NDP52 proteins target intracytosolic 569 
Shigella and Listeria to different autophagy pathways. J. Biol. Chem. 286, 570 
26987–95 571 
31  Komatsu, M. et al. (2006) Loss of autophagy in the central nervous system 572 
causes neurodegeneration in mice. Nature 441, 880–4 573 
32  Hara, T. et al. (2006) Suppression of basal autophagy in neural cells causes 574 
neurodegenerative disease in mice. Nature 441, 885–9 575 
33  Korac, J. et al. (2013) Ubiquitin-independent function of optineurin in 576 
autophagic clearance of protein aggregates. J. Cell Sci. 126, 580–92 577 
34  Morton, S. et al. (2008) Enhanced binding of TBK1 by an optineurin mutant 578 
that causes a familial form of primary open angle glaucoma. FEBS Lett. 582, 579 
997–1002 580 
35  Lussignol, M. et al. (2013) The herpes simplex virus 1 Us11 protein inhibits 581 
autophagy through its interaction with the protein kinase PKR. J. Virol. 87, 582 
859–71 583 
36  Chou, J. et al. (1990) Mapping of herpes simplex virus-1 neurovirulence to 584 
 28 
gamma 134.5, a gene nonessential for growth in culture. Science 250, 1262–6 585 
37  Orvedahl, A. et al. (2007) HSV-1 ICP34.5 confers neurovirulence by targeting 586 
the Beclin 1 autophagy protein. Cell Host Microbe 1, 23–35 587 
38  Ma, Y. et al. (2012) Inhibition of TANK binding kinase 1 by herpes simplex virus 588 
1 facilitates productive infection. J. Virol. 86, 2188–96 589 
39  Liang, Q. et al. (2014) Crosstalk between the cGAS DNA sensor and Beclin-1 590 
autophagy protein shapes innate antimicrobial immune responses. Cell Host 591 
Microbe 15, 228–38 592 
40  Watson, R.O. et al. (2015) The Cytosolic Sensor cGAS Detects Mycobacterium 593 
tuberculosis DNA to Induce Type I Interferons and Activate Autophagy. Cell 594 
Host Microbe 17, 811–9 595 
41  Whitley, R.J. and Gnann, J.W. (2002) Viral encephalitis: familiar infections and 596 
emerging pathogens. Lancet (London, England) 359, 507–13 597 
42  Abel, L. et al. (2010) Age-dependent Mendelian predisposition to herpes 598 
simplex virus type 1 encephalitis in childhood. J. Pediatr. 157, 623–9, 629.e1 599 
43  De Tiège, X. et al. (2008) The spectrum of herpes simplex encephalitis in 600 
children. Eur. J. Paediatr. Neurol. 12, 72–81 601 
44  Lahat, E. et al. (1999) Long term neurological outcome of herpes encephalitis. 602 
Arch. Dis. Child. 80, 69–71 603 
45  Whitley, R.J. et al. (1986) Vidarabine versus acyclovir therapy in herpes 604 
simplex encephalitis. N. Engl. J. Med. 314, 144–9 605 
 29 
46  Zhang, S.-Y. et al. (2013) TLR3 immunity to infection in mice and humans. Curr. 606 
Opin. Immunol. 25, 19–33 607 
47  Casrouge, A. et al. (2006) Herpes simplex virus encephalitis in human UNC-93B 608 
deficiency. Science 314, 308–12 609 
48  Zhang, S.-Y. et al. (2007) TLR3 deficiency in patients with herpes simplex 610 
encephalitis. Science 317, 1522–7 611 
49  Guo, Y. et al. (2011) Herpes simplex virus encephalitis in a patient with 612 
complete TLR3 deficiency: TLR3 is otherwise redundant in protective 613 
immunity. J. Exp. Med. 208, 2083–98 614 
50  Sancho-Shimizu, V. et al. (2011) Herpes simplex encephalitis in children with 615 
autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 121, 4889–616 
902 617 
51  Pérez de Diego, R. et al. (2010) Human TRAF3 adaptor molecule deficiency 618 
leads to impaired Toll-like receptor 3 response and susceptibility to herpes 619 
simplex encephalitis. Immunity 33, 400–11 620 
52  Andersen, L.L. et al. (2015) Functional IRF3 deficiency in a patient with herpes 621 
simplex encephalitis. J. Exp. Med. 212, 1371–9 622 
53  Zhang, S.-Y. et al. (2013) Mendelian predisposition to herpes simplex 623 
encephalitis. Handb. Clin. Neurol. 112, 1091–7 624 
54  Lafaille, F.G. et al. (2012) Impaired intrinsic immunity to HSV-1 in human iPSC-625 
derived TLR3-deficient CNS cells. Nature 491, 769–73 626 
 30 
55  Alexopoulou, L. et al. (2001) Recognition of double-stranded RNA and 627 
activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732–8 628 
56  Weber, F. et al. (2006) Double-stranded RNA is produced by positive-strand 629 
RNA viruses and DNA viruses but not in detectable amounts by negative-630 
strand RNA viruses. J. Virol. 80, 5059–64 631 
57  Jacquemont, B. and Roizman, B. (1975) Ribonucleic acid synthesis in cells 632 
infected with herpes simplex virus: characterization of viral high molecular 633 
weight nuclear RNA. J. Gen. Virol. 29, 155–65 634 
58  Balachandran, S. et al. (2000) Alpha/beta interferons potentiate virus-induced 635 
apoptosis through activation of the FADD/Caspase-8 death signaling pathway. 636 
J. Virol. 74, 1513–23 637 
59  Shaw, P.J. (2005) Molecular and cellular pathways of neurodegeneration in 638 
motor neurone disease. J. Neurol. Neurosurg. Psychiatry 76, 1046–57 639 
60  Charcot, J.-M. and Joffroy, A. (1869) Deux cas d’atrophie musculaire 640 
progressive avec lésions de la substance grise et des faiseaux antéro-latéraux 641 
de la moelle épinière. Arch. Physiol. Norm. Pathol. 2, 744–760 642 
61  Rowland, L.P. and Shneider, N.A. (2001) Amyotrophic lateral sclerosis. N. Engl. 643 
J. Med. 344, 1688–700 644 
62  Barber, S.C. et al. (2006) Oxidative stress in ALS: A mechanism of 645 
neurodegeneration and a therapeutic target. Biochim. Biophys. Acta - Mol. 646 
Basis Dis. 1762, 1051–1067 647 
 31 
63  Shi, P. et al. (2010) Mitochondrial dysfunction in amyotrophic lateral sclerosis. 648 
Biochim. Biophys. Acta 1802, 45–51 649 
64  Hirano, A. et al. (1984) Fine structural observations of neurofilamentous 650 
changes in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 43, 461–651 
70 652 
65  Zhao, W. et al. (2013) Immune-mediated mechanisms in the pathoprogression 653 
of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 8, 888–99 654 
66  Lomen-Hoerth, C. et al. (2002) The overlap of amyotrophic lateral sclerosis 655 
and frontotemporal dementia. Neurology 59, 1077–9 656 
67  Neumann, M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar 657 
degeneration and amyotrophic lateral sclerosis. Science 314, 130–3 658 
68  Rosen, D.R. et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are 659 
associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 660 
69  Sreedharan, J. et al. (2008) TDP-43 mutations in familial and sporadic 661 
amyotrophic lateral sclerosis. Science 319, 1668–72 662 
70  Kwiatkowski, T.J. et al. (2009) Mutations in the FUS/TLS gene on chromosome 663 
16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–8 664 
71  Deng, H.-X. et al. (2011) Mutations in UBQLN2 cause dominant X-linked 665 
juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211–5 666 
72  Renton, A.E. et al. (2014) State of play in amyotrophic lateral sclerosis 667 
genetics. Nat. Neurosci. 17, 17–23 668 
 32 
73  Maruyama, H. et al. (2010) Mutations of optineurin in amyotrophic lateral 669 
sclerosis. Nature 465, 223–6 670 
74  Khoris, J. et al. (2000) Coexistence of dominant and recessive familial 671 
amyotrophic lateral sclerosis with the D90A Cu,Zn superoxide dismutase 672 
mutation within the same country. Eur. J. Neurol. 7, 207–11 673 
75  Hand, C.K. et al. (2001) Compound heterozygous D90A and D96N SOD1 674 
mutations in a recessive amyotrophic lateral sclerosis family. Ann. Neurol. 49, 675 
267–71 676 
76  Hadano, S. et al. (2001) A gene encoding a putative GTPase regulator is 677 
mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 29, 166–73 678 
77  Fecto, F. (2011) <emph type=“ital”>SQSTM1</emph> Mutations in Familial 679 
and Sporadic Amyotrophic Lateral Sclerosis. Arch. Neurol. 68, 1440 680 
78  Le Ber, I. et al. (2015) TBK1 mutation frequencies in French frontotemporal 681 
dementia and amyotrophic lateral sclerosis cohorts. Neurobiol. Aging 36, 682 
3116.e5–8 683 
79  Williams, K.L. et al. (2015) Novel TBK1 truncating mutation in a familial 684 
amyotrophic lateral sclerosis patient of Chinese origin. Neurobiol. Aging 36, 685 
3334.e1–5 686 
80  Quigley, H.A. (2011) Glaucoma. Lancet (London, England) 377, 1367–77 687 
81  Friedman, D.S. et al. (2004) Prevalence of open-angle glaucoma among adults 688 
in the United States. Arch. Ophthalmol. (Chicago, Ill.  1960) 122, 532–8 689 
 33 
82  Quigley, H.A. (2011) Glaucoma. Lancet (London, England) 377, 1367–1377 690 
83  Minegishi, Y. et al. (2013) Enhanced optineurin E50K-TBK1 interaction evokes 691 
protein insolubility and initiates familial primary open-angle glaucoma. Hum. 692 
Mol. Genet. 22, 3559–67 693 
84  Fingert, J.H. (2011) Primary open-angle glaucoma genes. Eye (Lond). 25, 587–694 
95 695 
85  Kawase, K. et al. (2012) Confirmation of TBK1 duplication in normal tension 696 
glaucoma. Exp. Eye Res. 96, 178–80 697 
86  Ritch, R. et al. (2014) TBK1 gene duplication and normal-tension glaucoma. 698 
JAMA Ophthalmol. 132, 544–8 699 
87  Consortium, E.A. et al. (2015) Analysis of protein-coding genetic variation in 700 
60,706 humans, Cold Spring Harbor Labs Journals. 701 
88  Casanova, J.-L. et al. (2013) Immunology taught by human genetics. Cold 702 
Spring Harb. Symp. Quant. Biol. 78, 157–72 703 
89  Goncalves, A. et al. (2011) Functional dissection of the TBK1 molecular 704 
network. PLoS One 6, e23971 705 
90  Yordy, B. et al. (2012) A neuron-specific role for autophagy in antiviral defense 706 
against herpes simplex virus. Cell Host Microbe 12, 334–45 707 
91  Looker, K.J. et al. (2015) Global and Regional Estimates of Prevalent and 708 
Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS One 10, 709 
e0140765 710 
 34 
92  Yang, Y. et al. (2013) Clinical whole-exome sequencing for the diagnosis of 711 
mendelian disorders. N. Engl. J. Med. 369, 1502–11 712 
93  Lee, H. et al. (2014) Clinical exome sequencing for genetic identification of 713 
rare Mendelian disorders. JAMA 312, 1880–7 714 
94  Casanova, J.-L. (2015) Severe infectious diseases of childhood as monogenic 715 
inborn errors of immunity. Proc. Natl. Acad. Sci. U. S. A. 112, E7128–37 716 
95  Zhu, X. et al. (2014) One gene, many neuropsychiatric disorders: lessons from 717 
Mendelian diseases. Nat. Neurosci. 17, 773–81 718 
96  Boisson-Dupuis, S. et al. (2012) Inborn errors of human STAT1: allelic 719 
heterogeneity governs the diversity of immunological and infectious 720 
phenotypes. Curr. Opin. Immunol. 24, 364–78 721 
97  Bonnard, M. et al. (2000) Deficiency of T2K leads to apoptotic liver 722 
degeneration and impaired NF-kappaB-dependent gene transcription. EMBO 723 
J. 19, 4976–85 724 
98  Marchlik, E. et al. (2010) Mice lacking Tbk1 activity exhibit immune cell 725 
infiltrates in multiple tissues and increased susceptibility to LPS-induced 726 
lethality. J. Leukoc. Biol. 88, 1171–80 727 
99  McWhirter, S.M. et al. (2004) IFN-regulatory factor 3-dependent gene 728 
expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc. 729 
Natl. Acad. Sci. U. S. A. 101, 233–8 730 
100  Miyahira, A.K. et al. (2009) TANK-binding kinase-1 plays an important role 731 
 35 
during in vitro and in vivo type I IFN responses to DNA virus infections. J. 732 
Immunol. 182, 2248–57 733 
101  Perry, A.K. et al. (2004) Differential requirement for TANK-binding kinase-1 in 734 
type I interferon responses to toll-like receptor activation and viral infection. J. 735 
Exp. Med. 199, 1651–8 736 
102  Wang, R. et al. (2011) Activation of interferon signaling pathways in spinal 737 
cord astrocytes from an ALS mouse model. Glia 59, 946–58 738 
103  Hofer, M.J. et al. (2010) The type I interferon-alpha mediates a more severe 739 
neurological disease in the absence of the canonical signaling molecule 740 
interferon regulatory factor 9. J. Neurosci. 30, 1149–57 741 
104  van Boxel-Dezaire, A.H.H. et al. (2006) Complex modulation of cell type-742 
specific signaling in response to type I interferons. Immunity 25, 361–72 743 
105  Mankouri, J. et al. (2010) Optineurin negatively regulates the induction of 744 
IFNbeta in response to RNA virus infection. PLoS Pathog. 6, e1000778 745 
106  Sakaguchi, T. et al. (2011) Optineurin with amyotrophic lateral sclerosis-746 
related mutations abrogates inhibition of interferon regulatory factor-3 747 
activation. Neurosci. Lett. 505, 279–81 748 
107  Mattson, M.P. and Meffert, M.K. (2006) Roles for NF-kappaB in nerve cell 749 
survival, plasticity, and disease. Cell Death Differ. 13, 852–60 750 
108  Elion, G.B. (1983) The biochemistry and mechanism of action of acyclovir. J. 751 
Antimicrob. Chemother. 12 Suppl B, 9–17 752 
 36 
109  Miller, R.G. et al. (2007) Riluzole for amyotrophic lateral sclerosis (ALS)/motor 753 
neuron disease (MND). Cochrane database Syst. Rev. DOI: 754 
10.1002/14651858.CD001447.pub2 755 
110  Sambhara, D. and Aref, A.A. (2014) Glaucoma management: relative value and 756 
place in therapy of available drug treatments. Ther. Adv. Chronic Dis. 5, 30–43 757 
111  de Paula, C.Z. et al. (2015) An Overview of Potential Targets for Treating 758 
Amyotrophic Lateral Sclerosis and Huntington’s Disease. Biomed Res. Int. 759 
2015, 1–7 760 
112  Li, J. et al. (2012) Crystal structure of the ubiquitin-like domain of human 761 
TBK1. Protein Cell 3, 383–91 762 
113  Zhang, K.Y. et al. (2014) Ubiquilin 2: a component of the ubiquitin-proteasome 763 
system with an emerging role in neurodegeneration. Int. J. Biochem. Cell Biol. 764 
50, 123–6 765 
114  Weinreb, R.N. et al. (2014) The pathophysiology and treatment of glaucoma: a 766 
review. JAMA 311, 1901–11 767 
 768 
  769 
 37 
Box 1. Mouse models of TBK1 deficiency 770 
TBK1 is highly conserved in mammals, with human TBK1 protein sharing 99% 771 
homology with its mouse ortholog [13]. However, characterization of TBK1 function 772 
in vivo remains a major challenge, as homozygous deletion of TBK1 in mice results in 773 
embryonic lethality at embryonic day 14.5 due to severe hepatic tissue loss and 774 
apoptosis [97]. However, mice homozygous for a truncated allele (TBK1∆/∆) are viable, 775 
with minimal expression of truncated TBK1, which lacks kinase activity [98]. 776 
Macrophages from these mice have shown reduced IRF3 DNA-binding activity and 777 
IFN induction upon LPS induction. Heterozygous mice with one truncated allele 778 
(TBK1∆/+) are also viable although their immunological response to infection has not 779 
been studied [98]. Much of our understanding of TBK1 function in viral infections and 780 
upon stimulation with the synthetic analog of dsRNA, polyinosinic:polycytidylic acid 781 
(poly I:C) in vitro, has mainly come from observations in TBK1-deficient (TBK1-/-) 782 
mouse embryonic fibroblasts (MEFs) or macrophages exhibiting impaired IFN 783 
responses (IFN/α) or IFN-induced responses such as IP-10 (IFN-gamma-inducible 784 
protein 10) and Mx1  [38,99–101]. However, the autophagy function in TBK1 deficient 785 
mouse models has yet to be characterized.   786 
 787 
Box 2. Additional putative TBK1 aberrations: Dysfunctional autophagy in HSE?  IFN 788 
impairment in ALS-FTD? 789 
HSE in patients with AD TBK1 deficiency has been attributed to impaired type-I and 790 
type-III IFN production, similar to other HSE-causing genes of the TLR3-IFN signaling 791 
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pathways [46]. It would be of interest to further test whether autophagy defects are 792 
observed in these HSE patients. Although no mutations occur in the CCD2 domain of 793 
TBK1, which is particularly important for autophagy, the dominant negative HSE 794 
mutation has shown overall functional reduction in TBK1 which may also affect its 795 
autophagy function. Furthermore, the haploinsufficient TBK1 mutation in HSE, despite 796 
exhibiting moderate reduction (~50%) in protein levels in heterozygous cells, has not 797 
shown an impairment of the IFN pathway, even though the patient’s cells were shown 798 
to be susceptible to viral infection [6]. This might suggest that other TBK1 pathways 799 
could be affected. Assessing the role of autophagy is particularly relevant in the 800 
context of HSV1 infections because it has been shown to be critical in controlling HSV 801 
infection in post-mitotic neuronal cells [90]. Beyond TBK1-deficient HSE patients, 802 
whether or not this may reveal a general feature of HSE disease remains to be 803 
explored. A selection of the TBK1 mutations identified in ALS-FTD patients has been 804 
assessed for IFN signaling, presenting either complete impairment (T320QfsX40, 805 
I450KfsX15, V479EfsX4, R47H, M559R) or reduced IFNβ induction (R357Q) in patient 806 
cells (Table1). This suggests that these mutations may affect antiviral responses, 807 
although this parameter has not been specifically tested. Moreover, these mutations 808 
have been tested in an allele-specific manner, overexpressing the tagged mutants in 809 
HEK293T cells, but not in the context of an endogenous WT allele. Hence, the true 810 
effect of the mutation in heterozygosity has not been determined. Whether such IFN 811 
impairment could also contribute to ALS-FTD pathogenesis is a possibility that has not 812 
been explored either. Nevertheless, other studies using mouse models of ALS or in 813 
vitro studies that looked at the expression and effects of type I IFNs on CNS-resident 814 
cells have demonstrated a pleiotropic role of type I IFNs in neuronal survival, in which 815 
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they could confer protection or be detrimental to these cells, suggesting that IFN could 816 
be relevant to ALS pathogenesis [102–104].  Furthermore, optineurin-TBK1 complexes 817 
have been implicated in the regulation of IRF3-IFN responses following dsRNA or viral 818 
infections, suggestive of a possible crosstalk between the two different TBK1 819 
pathways in disease [20,39,105,106]. Of note, these TBK1 variants have not been 820 
tested for their role in NF-κB signaling which may also potentially affect 821 
neuroinflammation [107]. In fact, in NTG, the role of abnormal NF-κB signaling due to 822 
TBK1 duplications has been proposed as a pathogenic mechanism [10]. As such, the 823 
impact of TBK1 on other pathways may also contribute to disease in the context of 824 
heterozygous mutations. 825 
Box 3. Implications For Treatment Avenues 826 
Studies on HSE used to be hindered by the fact that this primarily childhood disease is 827 
lethal which made it difficult to trace the transmission of the underlying genes, until 828 
the advent of acyclovir [42,44]. Acyclovir is a nucleoside analogue with proven efficacy 829 
of inhibiting HSV-1 DNA replication which has significantly reduced mortality [108]. 830 
Unfortunately survivors still suffer from neurological sequelae and 831 
neuroinflammation [42,44]. ALS and FTD both have no cure, and current treatments 832 
involve palliative care with variable success. Riluzole (Rilutek©) is the only FDA-833 
approved drug that can delay ventilator dependence by few months for ALS patients 834 
although its mechanism is unknown [109]. Glaucoma patients rely on prostaglandin 835 
analogues or surgical procedures to relieve symptoms [110]. Broad effect treatment 836 
such as autophagy inducer rapamycin has been shown to be a promising ALS drug 837 
candidate [111]. However, given the implication of TBK1 in these diseases, perhaps 838 
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exploring TBK1 as a more defined target of novel therapeutics such as TBK1 activators 839 
would be a solution. As ALS, FTD and glaucoma are progressive diseases; there is an 840 
urgent need for neuroprotective treatments. HSE would on the other hand, benefit 841 
from treatments aimed at decreasing neuronal death or neuroinflammation 842 
associated with infection.  843 
  844 
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Figures & Legends 845 
 846 
Figure 1 – Disease-causing mutations in human TBK1. TBK1 is an 84 kDa, 729 amino-847 
acid protein that is composed of a kinase domain, an ubiquitin-like domain (ULD), and 848 
CCD1 (coiled-coiled domain 1) and CCD2. The kinase domain is critical for its activity 849 
to phosphorylate its various substrates, such as IRF3 [15], whereas the ULD domain 850 
regulates kinase activation and interactions with other proteins of the pathway [112]. 851 
The CCD1 domain harbors a leucine zipper (LZ) and helix-loop-helix (HLH) domains 852 
which specifically control dimerisation. The C-terminus CCD2 harbors an adaptor-853 
binding motif facilitating the interaction of TBK1 with its adaptors TANK, NAK–854 
associated protein (NAP1) and similar to NAP1 TBK1 adaptor (SINTBAD) [89]. Germline 855 
human TBK1 mutations reported in the literature to be disease-causing in (a) normal 856 
tension glaucoma (NTG), (b) herpes simplex encephalitis (HSE), (c) amyotrophic lateral 857 
sclerosis-frontotemporal dementia ALS-FTD, (d) FTD and (e) ALS and are shown with 858 
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respect to their amino acid position within the TBK1 protein. The black horizontal box 859 
in (a) indicates duplications in kbp that have been reported to include TBK1. Open 860 
circles represent LoF variants; filled circles represent missense variants.  (See Table 1). 861 
 862 
 863 
 864 
Key Figure, Figure 2 – Molecular Pathways of TBK1. TBK1 and IKKε function as the 865 
non-cannonical IkB kinases downstream of TLRs, RLRs, DDX3X, and DNA receptors 866 
leading to the activation of the transcription factors NF-kB (p65/p50) and IRFs (IRF3), 867 
resulting in the production of proinflammatory cytokines and antiviral IFNs. TLR3 868 
recognises dsRNA initiating the recruitment of adaptors such as TRIF and TRAF3 (TNF 869 
receptor-associated factor 3), which then activate TBK1 found complexed with its 870 
interacting proteins NAP1 (NF-kB-activating kinase-associated protein-1), SINTBAD 871 
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(similar to NAP1 TBK1 adaptor) and TANK. LPS recognition by TLR4 can also recruit 872 
TRIF and subsequently TRAF3 which mediates activation of TBK1. Activated TBK1 can 873 
then phosphorylate IRF3, leading to its homodimerisation and subsequent 874 
translocation into the nucleus where it induces the production of IFNs. Cytosolic RLRs 875 
and DDX3X, as well as DNA sensor cGAS signal via TBK1 following recognition of their 876 
ligands viral 5′-ppp RNA and DNA respectively. RLRs typically signal via the adaptor 877 
MAVS (mitochondrial antiviral-signaling protein; also known as IPS-1, CARDIF or VISA), 878 
which activates TBK1. cGAS detects dsDNA and stimulates STING (stimulator of 879 
interferon genes) to bind and activate TBK1 directly. TBK1 is also involved in 880 
autophagy where it directly phosphorylates the autophagy receptors optineurin and 881 
p62, which target cargo to the autophagosome. Ubiquilin-2 can also target 882 
ubiquitinated cargo to autophagosomes [113]. Target cargo may be pathogen or 883 
ubiquitinated protein aggregates. Proteins which genes have been reported to 884 
predispose to diseases are indicated in red, HSE; green, ALS or ALS-FTD; blue, NTG. 885 
Yellow denotes TBK1, where all pathways converge.  886 
 887 
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 888 
Figure 3 – Dynamic interplay between cells in CNS in ALS, FTD, HSE and NTG. In 889 
ALS/FTD, motor neurons accumulate toxic protein aggregates (e.g.: TDP-43 inclusions) 890 
which contribute to neurodegeneration. In addition to this, other cells are known to 891 
mediate neuroinflammation leading to cell death. Activated microglia and inflitrating 892 
monocytes and T cells produce inflammatory cytokines; and astrocytes are shown to 893 
downregulate their supportive function contributing to neurodegeneration [65]. In 894 
HSE, studies using iPSCs-derived neurons from a TLR3 deficient patient demonstrated 895 
that TLR3-dependent cell-intrinsic immunity in neurons and oligodendrocytes are 896 
critical in primary infection against HSV1 [54]. In NTG, progressive degeneration of 897 
retinol ganglion cells occurs which is poorly understood [114]. 898 
  899 
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Trends Box  900 
 HSE, in a subset of children, is caused by impaired antiviral IFN production 901 
due to monogenic mutations in the TLR3-IFN signalling pathway, including 902 
TBK1. 903 
 Due to advances in sequencing technologies, a number of new amyotrophic 904 
lateral sclerosis (ALS) or ALS-frontotemporal dementia (ALS-FTD) genes have 905 
been identified, five of which are known to be involved in autophagy, 906 
SQSTM1, VCP, OPTN, UBQLN2 and TBK1. These mutations are thought to 907 
contribute to disease pathogenesis possibly due to impaired autophagy. 908 
 The genetic aetiology of normal tension glaucoma (NTG) has recently been 909 
attributed to copy number variants found in chromosome region 12q14, 910 
specifically leading to duplications of the TBK1 gene. This duplication has 911 
been found to increase TBK1 transcript levels, suggesting a gain of function 912 
role forTBK1 in NTG. 913 
 Recent developments in the field of selective autophagy have implicated this 914 
evolutionarily conserved process in innate immunity and pathogen clearance, 915 
including neuronal cells. 916 
 917 
  918 
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Outstanding questions 919 
 What are the respective roles of IFN and autophagy in human TBK1 920 
disorders? Do they work independently or together to resolve/exacerbate 921 
inflammation? 922 
 Neuronal cells are the common cell in human TBK1 disorders, however what 923 
other cell types control TBK1-mediated neuroinflammation? 924 
 What is the mediator of tissue damage/neuroinflammation in these human 925 
TBK1 diseases? Do they point to the same culprit i.e. protein aggregates? Are 926 
protein aggregates a feature of herpes encephalitis? 927 
 Is there evidence for a viral trigger in the development of ALS/glaucoma ? 928 
Does IFN play a role in the development of ALS, FTD or glaucoma? 929 
 Could the dissection of TBK1 function provide us with new therapeutic 930 
strategies to treat for HSE, ALS, FTD, ALS-FTD or NTG? Common disease 931 
pathogenesis focusing on neuroprotective effects or pathways mediated by 932 
TBK1 may reveal more effective and targeted therapies for these diseases. 933 
Treatment to boost autophagy may be helpful in these diseases, i.e 934 
rapamycin to prevent cell toxicity and cell death, or drugs to boost 935 
proteasome function in patients with TBK1 deficiencies, so that the 936 
proteasomal ubiquitination pathway may help clear out toxic build up of 937 
protein aggregates. 938 
  939 
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Glossary 940 
 TBK1 (TANK-binding kinase 1): TBK1 is a kinase that functions downstream of 941 
multiple IFN inducing pathways that are activated following pathogen sensing 942 
and are mediated by Toll-like receptor 3 (TLR3), RIG-I-like receptors (RLRs) 943 
and cytosolic DNA sensors. Following activation, it phosphorylates cytosolic 944 
IRF3 or IRF7, which then dimerise and enter the nucleus to activate IFN 945 
production. 946 
 Trigeminal nerves: Trigeminal nerves are the nerves that innervate the 947 
cranium and are responsible for sensory and some motor functions in the 948 
face. Following primary infection, HSV1 may take this route to reach the 949 
central nervous system to cause acute infection.  950 
 Pattern recognition receptors (PRRs): These are innate immune receptors 951 
that form the first line of defence against pathogens. They recognise 952 
pathogen-associated molecular patterns (PAMPs) that are conserved across 953 
groups of pathogens. 954 
 TAR DNA-binding protein 43 (TDP-43): This is a nuclear protein that has a 955 
role in regulating gene expression. Mutations in its gene TARDBP can lead to 956 
its accumulation and aggregation in the cytoplasm of motor neurons, which is 957 
considered to be the hallmark of ALS and FTD. 958 
 Frontotemporal lobar dementia (FTD): is a disease that is characterised by 959 
progressive neuronal loss of the frontal and temporal lobes of the brain. 960 
 STAT1 deficiencies:  Several inborn mutations of human STAT1 have been 961 
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identified that exhibit allelic heterogeneity, different modes of inheritance 962 
and variable immunological/clinical phenotypes. AR complete and partial 963 
deficiencies predispose to bacterial and viral infections due to impaired IFN-γ, 964 
-α/β-mediated immunity; AD deficiency selectively underlies mycobacterial 965 
disease due to impaired IFN-γ mediated immunity; AD gain of function STAT1 966 
mutations, found exclusively in the coiled-coil domain of STAT1, give rise to 967 
autoimmunity and chronic mucocutaneous candidiasis due to increased IFN--968 
α/β response and impaired TH17 response [96]. 969 
 970 
 971 
Table 1. Molecular characterization of TBK1 variants reported in human diseases.  972 
Type of 
variant 
Mutation 
(location in a.a. 
or kbps) 
Premature 
STOP 
Expression Function 
Disease References mRNA level Protein level Optineurin 
binding 
IFN Allele-
specific 
Patient 
cells 
Allele-
specific 
Patient 
cells 
Frameshift 
p.T77WfsX4 Yes - Reduced - Reduced - - 
ALS-
FTD 
[8] 
p.T320QfsX40 Yes - - No - Impaired Impaired 
ALS-
FTD 
[8] 
p.S398PfsX11 Yes - Reduced - Reduced - - ALS [11] 
p.I450KfsX15 Yes - Reduced Truncated Reduced Impaired Impaired 
ALS-
FTD 
[8] 
p.V479EfsX4 Yes - - Truncated - Impaired Impaired 
ALS-
FTD 
[8] 
p.S518LfsX32 Yes - Reduced - Reduced - - ALS [11] 
Deletion 
p.D167del No - Normal - Normal - - ALS [11] 
p.G272_T331del No - Reduced - Reduced - - FTLD [11] 
p.E643del No - Normal - Reduced - - 
ALS; 
FTD; 
ALS-
FTD 
[8] [11] 
p.690-713del No - Normal 
Normal & 
truncated 
Normal & 
truncated 
Impaired Normal 
ALS-
FTD 
[8] 
Nonsense 
p.Y185X Yes - Reduced - - - - 
ALS-
FTD 
[8] 
p.R117X† Yes - Reduced - Reduced - - FTD [9] 
p.A417X Yes - Reduced - Reduced - - 
ALS-
FTD 
[8] 
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Missense 
p.R47H No - - Normal Normal Normal Impaired* 
ALS-
FTD 
[8] 
p.D50A No - Reduced No Reduced - Normal HSE [6] 
p.G159A No - Normal Normal Normal - Impaired HSE [6] 
p.R271L No - Normal - Normal - - FTD [11] 
p.K291E No - Normal - Normal - - FTD [11] 
p.L306I No - - - Normal - - FTD [9] 
p.R308Q No - - Normal - Normal Normal** 
ALS-
FTD 
[8] 
p.H322Y No - Normal - Normal - - ALS [11] 
p.R357Q No - - Normal - Reduced Impaired*** 
ALS-
FTD 
[8] 
p.K401E No - - - Reduced - - FTD [9] 
p.I515T No - Normal - Normal - - ALS [11] 
p.A535T No - Normal - Normal - - FTD [11] 
p.M559R No - - Normal - Impaired Impaired 
ALS-
FTD 
[8] 
p.M598V No - - - Normal - - 
ALS-
FTD 
[8] 
p.E696K No - - Normal Reduced Impaired Normal 
ALS-
FTD; 
FTD 
[8] [9] 
Duplication 
12:62, 980 – 63, 
670 kbp 
- - Elevated - - - - NTG [10] 
All variants are either novel or have allele frequency of <0.0005% in general population. 973 
Expression: assessed either allele specifically (in transfected cells) or in patient cells (expression of combined 974 
WT/mutant levels). 975 
Function: autophagy function was tested by optineurin binding; IFN activation was tested by either IRF3 binding, 976 
phosphorylation, or IFNβ promoter induction.  977 
* normal IRF3 binding but impaired IRF3 phosphorylation/IFNβ induction.  978 
** normal IRF3 binding, phosphorylation but reduced IFNβ induction. 979 
*** no IRF3 binding but reduced IRF3 phosphorylation/IFNβ induction. 980 
† patient also  carried a heterozygous deletion in OPTN exons 13-15 981 
 “-“ = not determined. 982 
Table 2. TBK1 variants of unknown pathogenicity reported in human diseases.  983 
Type of variant 
Mutation 
(location in a.a. or 
kbps) 
Mutation 
prediction 
Disease References 
Nonsense 
p.Q2X STOP ALS [7] [11] 
p.R117X STOP ALS [7] 
p.R357X STOP ALS [7] 
p.R440X STOP ALS; ALS-FTD; ALS-dementia [7] [8] [78] 
p.R444X STOP ALS [7] 
p.Y482X STOP ALS-FTD [78] 
p.S499X STOP ALS [7] 
p.Q655X STOP ALS-FTD [78] 
Frameshift 
p.T156RfsX6 STOP ALS-FTD [78] 
p.T278fs n.a. ALS [7] 
p.L399fs n.a. ALS [79] 
p.V421fs n.a. ALS [7] 
p.T462fs n.a. ALS [7] 
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p.D500fs n.a. ALS [7] 
p.E550fs n.a. ALS [7] 
p.Q629fs n.a. ALS [7] 
Deletion p.E640del n.a. ALS [7] 
Splice 
p.180sp n.a. ALS [7] 
p.331sp n.a. ALS [7] 
p.587sp n.a. ALS [7] 
c.1960-2A>G; 
p.653sp 
n.a. ALS-FTD [78] 
Missense 
p.T4A Probably damaging FTD [78] 
p.L11S Possibly damaging ALS [7] 
p.N22H* Probably damaging ALS [7] 
p.N22D Probably damaging ALS [7] 
p.R25H Probably damaging ALS [7] 
p.G26E Probably damaging ALS [78] 
p.Y105C Possibly damaging ALS-FTD [8] 
p.N129D Possibly damaging ALS [7] 
p.V132E Probably damaging ALS [7] 
p.R134H Probably damaging ALS [7] 
p.R143C Probably damaging ALS [78] 
p.S151C Probably damaging ALS [7] 
p.S151F Probably damaging ALS; NTG [7] [10] 
p.G217R Probably damaging ALS [7] 
p.R228H Probably damaging ALS [7] 
p.I257T Probably damaging ALS [7] 
p.L277V Benign ALS [7] 
p.I305T Possibly damaging ALS-FTD [8] 
p.L306I Possibly damaging NTG [10] 
p.T320I Benign ALS [78] 
p.T331I Benign ALS [7] 
p.T343S Probably damaging ALS [7] 
p.Y394D Possibly damaging ALS [7] 
p.R440Q* Probably damaging ALS [7] 
p.V464A Benign NTG [10] 
p.C471Y Benign ALS [7] 
p.I522M Possibly damaging ALS [7] 
p.A571V Benign ALS-FTD [8] 
p.Q565P Probably damaging ALS [7] 
p.Q581H Probably damaging ALS [7] 
p.M662T Benign ALS-FTD [78] 
p.I710N* Benign ALS [7] 
Duplication 
12:62, 900 – 63, 
680 kbp 
n.a. NTG [10] 
12:62, 760 – 63, 
410 kbp 
n.a. NTG [10] 
12:63, 060 – 63, 
360 kbp 
n.a. NTG [10] 
12:64,802 – 65 
,099 kbp 
n.a. NTG [85] 
12:64,830 – 65, 
096 kbp 
n.a. NTG [86] 
 984 
Mutation predictions were predicted by online tool PolyPhen-2 985 
(http://genetics.bwh.harvard.edu/pph2/index.shtml).  986 
n.a.= not applicable. 987 
* Mutations also found in controls. 988 
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